Clinical-stage drug platform company Stuart Therapeutics Inc announced on Tuesday that it has completed the phase III study of its lead therapeutic candidate ST-100 (vezocolmitide) for the treatment of Dry Eye Disease.

Topline data results are expected to be released in February 2025.

The phase III, randomised, double-blind, vehicle-controlled trial is assessing the efficacy, safety and tolerability of ST-100 (vezocolmitide) for the treatment of Dry Eye Disease. Patients were treated with the product or placebo for one month, following a two-week observation period. The study was initiated in December 2023 at one site in the United States and completed at multiple sites in Australia.

ST-100 (vezocolmitide) is a patented formulation comprising vezocolmitide, a collagen mimetic peptide that selectively repairs disease-damaged collagen in the eye. This is intended to provide both restoration of the collagen matrix and structures in the eye and homeostatic cell signalling by those structures.